# Impact of sympathetic hyperactivity induced by brain microglial activation on organ damage in sepsis with chronic kidney disease

**Authors:** Masaaki Nishihara, Keisuke Shinohara, Shota Ikeda, Tomohiko Akahoshi, Hiroyuki Tsutsui

PMC · DOI: 10.1186/s40560-024-00742-2 · Journal of Intensive Care · 2024-09-02

## TL;DR

This study shows that brain microglial activation increases sympathetic nerve activity, worsening organ damage in sepsis patients with chronic kidney disease.

## Contribution

The novel finding is that microglial activation in the hypothalamus exacerbates sepsis outcomes in CKD through heightened sympathetic activity.

## Key findings

- Rats with CKD and sepsis showed increased sympathetic nerve activity and organ dysfunction.
- Minocycline reduced sympathetic activation and improved hemodynamics and organ damage in septic CKD rats.
- Microglial activation in the PVN may drive systemic hemodynamic changes in sepsis with CKD.

## Abstract

Sympathetic nerve activity (SNA) plays a central role in the pathogenesis of several diseases such as sepsis and chronic kidney disease (CKD). Activation of microglia in the paraventricular nucleus of the hypothalamus (PVN) has been implicated in SNA. The mechanisms responsible for the adverse prognosis observed in sepsis associated with CKD remain to be determined. Therefore, we aimed to clarify the impact of increased SNA resulting from microglial activation on hemodynamics and organ damage in sepsis associated with CKD.

In protocol 1, male Sprague–Dawley rats underwent either nephrectomy (Nx) or sham surgery followed by cecal ligation and puncture (CLP) or sham surgery. After CLP, Nx-CLP rats exhibited decreased blood pressure, increased heart rate, elevated serum creatinine and bilirubin levels, and decreased platelet count compared to Nx-Sham rats. Heart rate variability analysis revealed an increased low to high frequency (LF/HF) ratio in Nx-CLP rats, indicating increased SNA. Nx-CLP rats also had higher creatinine and bilirubin levels and lower platelet counts than sham-CLP rats after CLP. In protocol 2, Nx-CLP rats were divided into two subgroups: one received minocycline, an inhibitor of microglial activation, while the other received artificial cerebrospinal fluid (CSF) intracerebroventricularly via an osmotic minipump. The minocycline-treated group (Nx-mino-CLP) showed attenuated hypotensive and increased heart rate responses compared to the CSF-treated group (Nx-CSF-CLP), and the LF/HF ratio was also decreased. Echocardiography showed larger left ventricular dimensions and inferior vena cava in the Nx-mino-CLP group. In addition, creatinine and bilirubin levels were lower and platelet counts were higher in the Nx-mino-CLP group compared to the Nx-CSF-CLP group.

In septic rats with concomitant CKD, SNA was significantly enhanced and organ dysfunction was increased. It has been suggested that the mechanism of exacerbated organ dysfunction in these models may involve abnormal systemic hemodynamics, possibly triggered by activation of the central sympathetic nervous system through activation of microglia in the PVN.

The online version contains supplementary material available at 10.1186/s40560-024-00742-2.

## Linked entities

- **Chemicals:** minocycline (PubChem CID 54675783)
- **Diseases:** chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Diseases:** CKD (MESH:D051436), hypotensive (MESH:D007022), sympathetic hyperactivity (MESH:D006948), blood pressure (MESH:D006973), cecal (MESH:D002429), organ dysfunction (MESH:D009102), organ damage (MESH:D000092124), sepsis (MESH:D018805)
- **Chemicals:** bilirubin (MESH:D001663), minocycline (MESH:D008911), Nx (-), creatinine (MESH:D003404)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11367766/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11367766/full.md

---
Source: https://tomesphere.com/paper/PMC11367766